Bristol-myers Squibb Compnay

Rishikesh Narayan

Susheel Jethanand Nara

Srinivas Cheruku

Dean A Wacker

Kandhasamy Sarkunam

Firoz Ali Jaipuri

Srinivas Jogi

Soodamani Thangavel

Pavan Kalyan Kathi

Subba Reddy Bandreddy

Wei Meng

Ramesh Kumar Sistla

Guohua Zhao

Yanting Huang

Elizabeth Anne Jurica

David S Yoon

Rushith Kumar Anumula

Ximao Wu

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, when Q is: (i) halo, cyano, hydroxyl, NRR, C(O)OH, C(O)NH, Calkyl substituted with zero to 6 R, or P(O)RR, or (ii) L R; and A, X, X, X, X, Z, Z, R, R, R, R, R, R, R, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Substituted amide compounds useful as farnesoid X receptor modulators

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is Calkenyl or Calkynyl, each substituted with zero to 2 R; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Substituted bicyclic compounds as farnesoid X receptor modulators

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R; and A, X, X, X, X, Z, Z, R, R, R, R, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

The present invention provides compounds of Formula (I): 

Bridged bicyclic compounds as farnesoid X receptor modulators

Growing community of inventors

Mumbai, India

Rishikesh Narayan